Citrafarm for the pharmaceutical industry, a strategy is to build leading positions in defined business segments where there are a high unmet medical need and a demand for improved product presentations, Injectables, Emergency Care, Hospital-initiated Medicines, Ophthalmics and Unlicensed Medicines.
Our plans for growth are based on four principles:
Building on an exceptionally strong commercial organization,
we have a proven capability in. developing and distributing new products.
Internationalisation
We are building a truly international presence. In the Middle East, we are focused on the Gulf Co-operation with a forecast high growth in healthcare spending. We have established marketing Office in Tunisia , This will enable us to sell our high-quality products to all sectors of the market. We are also adding depth to our distribution partnerships in Africa and Asia moving from purely supplying on tenders to creating demand at hospital level in several markets.
Manufacturing Excellence
our manufacturer Partners have invested and upgraded in-house facilities to increase capacity, shorten lead times and support the flexibility needed for international markets to manufacture sterile injectables and other dosage form products. We choose molecules with established need and where the quality of the product is recognized and in demand. By late 2018 we will introduce more products to our list focused on a high value, a sterile dosage form for hospital products.
Maximising our portfolio
We invest in expanding our products range, adding line extensions to maximize the market opportunities and also adding new products based on known drugs where there is a commercial opportunity when presented in the dosage forms which we specialize in manufacturing.